References
1. Church CO, Stevens DL, Fugate SE. Diabetic ketoacidosis associated with aripiprazole. Diabet Med2005;22:1440–1443.
2. Nasrallah HA, Newcomer JW. Atypical antipsychotics and metabolic dysregulation. J Clin Psychopharmacol 2004;24:S7–S14.
3. Jin H, Meyer JM, Jeste DV. Atypical antipsychotics and glucose dysregulation: a systematic review.Schizophr Res 2004;71: 195–212.
4. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004;65:857–863.
5. Meyer JM, Leckband SG, Loh C, et al. Quetiapine-induced diabetes with metabolic acidosis. Int Clin Psychopharmacol 2004;19:169–171.
6. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000;26:903–912.
7. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry2001;62(suppl 27):15–26.
8. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry2001;62(suppl 27):27–34.
10. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337–345.
11. Dwyer DS, Liu Y, Bradley RJ. Dopamine antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci Lett 1999;274:151–154.
12. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59–64.
13. Wilson DR, D'Souza L, Sarkar N, et al. New onset diabetes and ketoacidosis with atypical antipsychotics. Schizophr Res 2002;59:1–6.